RxDoctor Payments Data

Windy Olaya, MD

Plastic and Reconstructive Surgery · Orange, CANPI 1508063934

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $11,925 of the $14,129 with a category attached, or 84.4%. 18 manufacturers reported payments, led by Mentor Worldwide LLC at 33.8% of the total. 2025 is the largest year on record at $6,792, 9.8 times the $695 reported in 2019.

$14,129in general payments, 2019–2025

Across 296 payments — averaging $47.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mentor Worldwide LLC$5K
  • Integra Lifesciences Corporation$4K
  • AbbVie$4K
  • Tactile Systems Technology Inc$457
  • RTI Surgical, Inc$455
  • Sientra, Inc.$295
  • plus $753 from 12 others

What the payments were for

  • Food & beverage$11,92584%
  • Other$2,20416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,129 in reported general payments places this provider in the 85th percentile of 349 plastic and reconstructive surgery providers in California.

See all plastic and reconstructive surgery providers in California

Medicare billing

Part B allowed, 2024
$160,685
Medicare patients
177
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$110
Montelukast Sodium11$73
Cephalexin15$63
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$35

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →